BNGO Bionano Genomics, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1411690 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY22.0%
TTM EPS YoY84.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin48.0%
Operating margin-97.1%
Net margin-96.9%
FCF margin—
EBITDA margin-76.0%
Returns
ROE-77.2%
ROA-48.0%
ROIC (approx.)-67.6%
Asset turnover0.50x
Leverage & solvency
Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-17.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $28.51M | $30.78M |
| Cost of revenue | $15.32M | $30.40M |
| Gross profit | $13.19M | $380,000 |
| R&D expense | $11.37M | $24.80M |
| SG&A expense | $35.15M | $51.85M |
| Operating income | -$33.34M | -$103.98M |
| Pretax income | -$26.33M | -$111.98M |
| Income tax | $67,000 | $33,000 |
| Net income | -$26.39M | -$112.02M |
| EBITDA | -$23.81M | -$89.96M |
| EPS (basic) | -4.85 | -88.13 |
| EPS (diluted) | -4.85 | -88.13 |
| Weighted avg. shares (diluted) | 5.45M | 1.27M |
| Balance sheet | ||
| Cash & equivalents | $2.99M | $9.17M |
| Short-term investments | $16.28M | $302,000 |
| Receivables | $5.20M | $4.75M |
| Inventory | $7.83M | $13.28M |
| Current assets | $45.39M | $39.49M |
| PP&E, net | $14.85M | $19.22M |
| Intangibles | $4.34M | $9.71M |
| Total assets | $73.58M | $76.67M |
| Current liabilities | $22.94M | $37.34M |
| Total liabilities | $29.16M | $41.30M |
| Shareholders' equity | $44.42M | $35.38M |
| Shares outstanding | 10.74M | 1.87M |
| Cash flow statement | ||
| Operating cash flow | -$16.34M | -$68.92M |
| Investing cash flow | -$12.75M | $73.84M |
| Financing cash flow | $24.04M | -$13.69M |
| Depreciation & amortization | $9.53M | $14.02M |
| Stock-based compensation | $4.53M | $9.74M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.